Result of General Meeting
4 November 2024
Nuformix plc
("Nuformix" or the "Company")
Result of General Meeting
Nuformix plc (LSE:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces that at the General Meeting of the Company held earlier today all resolutions put to shareholders were duly passed and approved by way of a show of hands. The proxies received ahead of the General Meeting, are reported below:
| Resolution | Ordinary/ Special | For |
| Against |
| Total votes cast |
No. of votes | % | No. of votes | % | ||||
1 | Subdivision of the ordinary shares
| Ordinary | 164,225,020 | 98.00% | 3,356,013 | 2.00% | 167,581,033 |
2 | To authorise the directors to allot shares
| Ordinary | 163,856,186 | 97.99% | 3,361,741 | 2.01% | 167,217,927 |
3 | To authorise the directors to disapply pre-emption rights
| Special | 163,856,186 | 98.04% | 3,273,557 | 1.96% | 167,129,743 |
4 | Amendment of the Company's Articles of Association
| Special | 163,856,186 | 98.04% | 3,273,557 | 1.96% | 167,129,743 |
A vote withheld is not a vote in law and is not counted in the calculation of votes validly cast for or against a resolution.
Full details of the Resolutions are contained in the Notice of General Meeting which is available, appended to the Prospectus, on the Company's website at: https://nuformix.com/document-center/
Following the passing of the Resolutions at the General Meeting, the expected timetable of events remains the same as documented in the Prospectus and is as follows:
2024 | |
Record Date for the Capital Reorganisation | 6.00 p.m. on 4 November |
Admission of New Ordinary Shares effective and commencement of dealing | 8.00 a.m. on 5 November
|
Expected date for CREST accounts to be credited | 5 November |
Despatch of definitive certificates (where applicable) expected by no later than | 11 November
|
Admission and Total Voting Rights
An application has been made to the London Stock Exchange for the 600,000,000 New Ordinary Shares, to be issued pursuant to the conditional £300,000 fundraise announced on 20 September 2024, to be admitted to the equity shares (transition) category of the Financial Conduct Authority's Official List and to trading on the Main Market of the London Stock Exchange ("Admission"). It is expected that Admission and unconditional dealings in the New Ordinary Shares will commence on the London Stock Exchange at 8.00 a.m. on 5 November 2024.
Following Admission of the New Ordinary Shares, the total number of Ordinary Shares in issue will be 1,419,309,368, each with one voting right. The Company does not hold any rights in treasury. The total voting rights figure is therefore 1,419,309,368 and can be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interest in, or a change of their interest in, the Company under the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority.
Terms used in this announcement shall, unless the context otherwise requires, be as defined in the Prospectus published by the Company on 16 October 2024.
Enquiries:
Nuformix plc |
|
Dr Dan Gooding, Executive Director
| Via IFC Advisory
|
CMC Markets | |
Douglas Crippen | +44 (0) 20 3003 8632 |
IFC Advisory Limited | |
Tim Metcalfe Zach Cohen | +44 (0) 20 3934 6630 nuformix@investor-focus.co.uk |
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has a pipeline of preclinical assets with potential for significant value and early licensing opportunities.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.